Navigation Links
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
Date:12/7/2008

ment Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease" was presented today at the ASH annual meeting by Dr. Alexander Roeth of the Department of Hematology at the University Hospital of Essen in Essen, Germany.

Dr. Roeth and his colleagues investigated the potential effect of eculizumab therapy in one patient with CAD, a rare and severe disease characterized by the production of circulatory cold agglutinins, a type of monoclonal antibody that lead to hemolysis. Conventional treatments for CAD, including corticosteroids and immunosuppressive drugs, are ineffective in many patients.

"We currently lack effective treatment options for patients with CAD," noted Dr. Roeth. "Given these promising initial observations, clinical research is needed to determine the therapeutic potential of eculizumab in patients with CAD."

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commission (EC) also approved the use of Soliris for the treatment of patients with PNH. Soliris is the first therapy approved in Europe for the treatment of PNH and was the first medicinal product to receive EC approval under the EMEA Accelerated Assessment Procedure. Soliris is not approved for the treatment of atypical Hemolytic Uremic Syndrome (aHUS) and Cold Agglutinin Disease (CAD).

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established.

The
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
11. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Unchained Labs, a refreshingly new biologic ... PEGS conference and launches the UNit — the first ... The Essential Protein Engineering Summit takes place in ... The UNit lets drug discovery researchers look at more ... Its 7 applications, 144 sample a day throughput and ...
(Date:5/4/2015)... , May 4, 2015 The Pharmacy ... Survey, which confirmed that pharmacy has shifted toward a ... active pharmacists and managers, there is an incredible opportunity ... in the next decade. In a ... site, Essential Insights , Eden Sulzer, director ...
(Date:5/4/2015)... 4, 2015  Verus Healthcare, Inc. recently completed its ... Care Club in 2012.  Since that original acquisition, the ... medical equipment (DME) industry by 1,000%.  Verus Healthcare now ... supply needs and processes nearly 14,000 new orders per ... years ago, the systems and processes weren,t in place ...
Breaking Medicine Technology:Unchained Labs Lets the UNit Loose 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 3Verus Healthcare Celebrates 1,000% Growth on Third Anniversary 2
... Cyberonics, Inc. (Nasdaq: CYBX ) today announced ... Browne, Chief Financial Officer, will present at the 22nd Annual ... November 30, 2010 at 1:30 PM ET.  The conference session ... will be presented.  Piper Jaffray will host a webcast of ...
... /PRNewswire-FirstCall/ -- AVANIR ... the pricing of an underwritten public offering of 20,000,000 shares ... per share.  The offering is expected to close on or ... addition, AVANIR has granted the underwriters a 30-day option to ...
Cached Medicine Technology:Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference 2AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 Ticket Down ... 2015 International Champions Cup (ICC) . While the World ... and is held every four years, the International Champions Cup ... the tournament saw the all-time attendance record for soccer in ... from the Big House at the University of Michigan. This ...
(Date:5/4/2015)... and Seattle, WA (PRWEB) May 04, 2015 ... formation of a collaboration to facilitate development of NM108, ... ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. ... MiDROPS™ formulation platform developed by EyeCRO, which can deliver ... via a topical eyedrop. , Under the terms ...
(Date:5/4/2015)... 04, 2015 Ticket Down is a reputable ... Paul Jones Arena in Charlottesville, VA. McCartney is ... the music business and this beloved performer continues to roll ... former member of two legendary groups: Wings and The Beatles, ... business since 2013 on the “Out There” tour and has ...
(Date:5/4/2015)... 04, 2015 New findings released today ... Association (ABTA) show that people diagnosed with a brain ... options, including clinical trials, at the time of diagnosis, ... difficult decisions about their course of treatment. The release ... first nationwide brain tumor volunteer network, the ABTA CommYOUnity™, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Pricing Healthcare ... to $3,000) of one patient receiving care at St. ... The procedure must be performed by July 15th, 2015, ... pay in full up front and forego the filing of ... more economically burdensome every year, and it devastates more and ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at John Paul Jones Arena in Charlottesville, VA: Ticket Down Slashes Paul McCartney Ticket Prices in Charlottesville at the John Paul Jones Arena 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3
... like a stage “, written by William Shakespeare where he ... to listen but a little difficult to accept when it ... aging, very little is done to understand the psychological and ... been embarrassed by the odd behavior of old people in ...
... exercises can keep the brain young and improve its working ... aerobic exercises keeps the brain// younger. ,Su Doku, ... placed from 1 through 9 in each cell of a ... subgrids (called "regions"), starting with various numerals given in some ...
... after 5 years of Tamoxifen therapy is found to ... cancer is the second leading cause of cancer// in ... and various risk factors are attributed for the occurrence ... initially involves removal of the entire breast or part ...
... A 72 year old mystery about cholesterol synthesis which ... been cracked by Nobel laureates. // ,The Shoenheimer ... first evidence for end-product feedback regulation of a biosynthetic ... synthesized large amounts of cholesterol when fed a low-cholesterol ...
...
... credit. Magnetic Resonance Spectrometry (MRS) as is it called ... such as brain abscess, and an accurate// and rapid ... help distinguish between brain tumor and other types of ... ,Several hundred serious brain infections such as abscesses and ...
Cached Medicine News:Health News:Do not regret growing older, It is a privilege denied to many 2Health News:Mental exercises reduces brain ageing 2Health News:Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence 2
... procedures where stability, access, and precise, ... cantilevered low attenuation carbon fiber tabletop ... radiolucent area is free of cross ... unobstructed C-Arm positioning. Functional design provides ...
...
... Immunoassay Control is a ... designed to complement the ... Immunoassay Plus Controls. This ... to include more complex ...
Liquichek Cardiac Markers Plus Control is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: